These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39223664)

  • 1. Tilorone mitigates the propagation of α-synucleinopathy in a midbrain-like organoid model.
    Zhang Q; Liu M; Xu Y; Lee J; Jones B; Li B; Huang W; Ye Y; Zheng W
    J Transl Med; 2024 Sep; 22(1):816. PubMed ID: 39223664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy.
    Parmasad JA; Ricke KM; Nguyen B; Stykel MG; Buchner-Duby B; Bruce A; Geertsma HM; Lian E; Lengacher NA; Callaghan SM; Joselin A; Tomlinson JJ; Schlossmacher MG; Stanford WL; Ma J; Brundin P; Ryan SD; Rousseaux MWC
    Cell Death Dis; 2024 Apr; 15(4):246. PubMed ID: 38575601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein.
    Howe JW; Sortwell CE; Duffy MF; Kemp CJ; Russell CP; Kubik M; Patel P; Luk KC; El-Agnaf OMA; Patterson JR
    Parkinsonism Relat Disord; 2021 Aug; 89():41-47. PubMed ID: 34218047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced human iPSC-based preclinical model for Parkinson's disease with optogenetic alpha-synuclein aggregation.
    Kim MS; Ra EA; Kweon SH; Seo BA; Ko HS; Oh Y; Lee G
    Cell Stem Cell; 2023 Jul; 30(7):973-986.e11. PubMed ID: 37339636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling α-Synucleinopathy in Organotypic Brain Slice Culture with Preformed α-Synuclein Amyloid Fibrils.
    Roux A; Wang X; Becker K; Ma J
    J Parkinsons Dis; 2020; 10(4):1397-1410. PubMed ID: 32716318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-synuclein pathology is associated with astrocyte senescence in a midbrain organoid model of familial Parkinson's disease.
    Muwanigwa MN; Modamio-Chamarro J; Antony PMA; Gomez-Giro G; Krüger R; Bolognin S; Schwamborn JC
    Mol Cell Neurosci; 2024 Mar; 128():103919. PubMed ID: 38307302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy.
    Chatterjee D; Sanchez DS; Quansah E; Rey NL; George S; Becker K; Madaj Z; Steiner JA; Ma J; Escobar Galvis ML; Kordower JH; Brundin P
    J Parkinsons Dis; 2019; 9(2):315-326. PubMed ID: 30932894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GV-971 attenuates α-Synuclein aggregation and related pathology.
    Yu Z; Yang Y; Chan RB; Shi M; Stewart T; Huang Y; Liu Z; Lan G; Sheng L; Tian C; Yang D; Zhang J
    CNS Neurosci Ther; 2024 Feb; 30(2):e14393. PubMed ID: 37563872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal Afferent BDNF Is Disrupted by Synucleinopathy and Partially Restored by STN DBS.
    Miller KM; Patterson JR; Kochmanski J; Kemp CJ; Stoll AC; Onyekpe CU; Cole-Strauss A; Steece-Collier K; Howe JW; Luk KC; Sortwell CE
    J Neurosci; 2021 Mar; 41(9):2039-2052. PubMed ID: 33472823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterozygous loss of Engrailed-1 and α-synucleinopathy (En1/SYN): A dual-hit preclinical mouse model of Parkinson's disease, analyzed with artificial intelligence.
    Stetzik L; Mercado G; Steiner JA; Lindquist A; Gilliland C; Schulz E; Meyerdirk L; Smith L; Molina J; Moore DJ
    Neurobiol Dis; 2024 Oct; 200():106647. PubMed ID: 39187209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow Progressive Accumulation of Oligodendroglial Alpha-Synuclein (α-Syn) Pathology in Synthetic α-Syn Fibril-Induced Mouse Models of Synucleinopathy.
    Uemura N; Uemura MT; Lo A; Bassil F; Zhang B; Luk KC; Lee VM; Takahashi R; Trojanowski JQ
    J Neuropathol Exp Neurol; 2019 Oct; 78(10):877-890. PubMed ID: 31504665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GDNF/RET Signaling Pathway Activation Eliminates Lewy Body Pathology in Midbrain Dopamine Neurons.
    Chmielarz P; Er Ş; Konovalova J; Bandres L; Hlushchuk I; Albert K; Panhelainen A; Luk K; Airavaara M; Domanskyi A
    Mov Disord; 2020 Dec; 35(12):2279-2289. PubMed ID: 32964492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease.
    Yang Y; Song JJ; Choi YR; Kim SH; Seok MJ; Wulansari N; Darsono WHW; Kwon OC; Chang MY; Park SM; Lee SH
    Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2110746119. PubMed ID: 35858361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lewy Body-like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and α-Synuclein Mutations.
    Jo J; Yang L; Tran HD; Yu W; Sun AX; Chang YY; Jung BC; Lee SJ; Saw TY; Xiao B; Khoo ATT; Yaw LP; Xie JJ; Lokman H; Ong WY; Lim GGY; Lim KL; Tan EK; Ng HH; Je HS
    Ann Neurol; 2021 Sep; 90(3):490-505. PubMed ID: 34288055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models.
    Mazzulli JR; Zunke F; Isacson O; Studer L; Krainc D
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):1931-6. PubMed ID: 26839413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production.
    Tapias V; Hu X; Luk KC; Sanders LH; Lee VM; Greenamyre JT
    Cell Mol Life Sci; 2017 Aug; 74(15):2851-2874. PubMed ID: 28534083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
    Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
    Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.